On December 17, 2025 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the Company will participate in the following investor events:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026
The Company will host an investor webcast on Friday, January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT to review results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. The webcast will include commentary from the Company’s senior management and Dr. Geoffrey Ku, Associate Attending physician on the Gastrointestinal Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. The webcast will take place following the oral presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026.
44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026
The Company will webcast its corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference. Renee Gala, president and chief executive officer, will provide an overview of the company strategy and a business update on Tuesday, January 13, 2026, at 11:15 a.m. PST / 7:15 p.m. GMT.
Audio webcasts of the presentations may be accessed via the Investors section of the Jazz Pharmaceuticals website at View Source A replay of the webcasts will be available on the website for 30 days.
(Press release, Jazz Pharmaceuticals, DEC 17, 2025, View Source [SID1234661512])